Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid
Executive Summary
Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.
You may also be interested in...
Lupin Hit By US Settlement, Japan Injectables Selloff
Despite 10% revenue growth, Lupin ended up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. The firm is now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
Lupin Q2 Hit By US Settlement, Japan Injectables Selloff
Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
Advances On the Biosimilar Litigation Battlefield
A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.